Incannex Healthcare Limited (IXHL) AI Stock Analysis
IXHL AI stock analysis summary
AI ResearchIncannex Healthcare Limited (IXHL) is a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies. The company generated $86,000 in revenue in FY2025 alongside a net income of -$46.9M and $0 in trailing twelve-month revenue. Despite operational losses, it maintains a strong balance sheet with $67.7M in cash and short-term investments against total debt of $96,000.
- Market cap
- $35.4M
- Revenue (TTM)
- $0
- P/E
- — fwd 3.8x
- 1Y return
- -73.1% S&P 500 16.8%
- Avg. target
- $18.64 561.0% vs last close
Bull case
- The company holds a strong cash cushion of $67.7M against minimal debt of $96,000, yielding net cash of $67.6M as of June 30, 2026.
- Analyst sentiment includes 1 Strong Buy rating with a mean price target of $18.64, which is 561.0% above the last close of $2.82.
- The stock trades at a price-to-book ratio of 0.5x, well below its shareholders' equity of $67.4M.
Bear case
- Revenue for the trailing twelve months was $0, with quarterly revenue falling 100.0% year-over-year in the period ended June 30, 2026.
- The company incurred a net loss of -$46.9M and burned -$12.5M in free cash flow during FY2025.
- The stock has lost 73.1% over the past year, significantly trailing the S&P 500 return of 16.8%.
What Incannex Healthcare does
Incannex Healthcare Limited specializes in the research, development, and commercialization of medicinal cannabinoid and psychedelic pharmaceutical products in Australia. Its product portfolio includes ultrapure tetrahydrocannabinol (APIRx-1801), cannabidiol (APIRx-1802), and cannabigerol (APIRx-1803). The company has advanced candidates into clinical trials, including IHL-42X for obstructive sleep apnea and Psi-GAD for generalized anxiety disorder, both in Phase IIa. Its pipeline also features MedChew Dronabinol for chemotherapy-induced nausea and CanChew Plus for irritable bowel syndrome, alongside pre-clinical programs evaluating IHL-675A for inflammatory lung disease and rheumatoid arthritis, as well as therapies for Parkinson's disease, dementia, and restless legs syndrome.
Growth and profitability
Incannex Healthcare experienced a 5-year revenue compound annual growth rate of -32.2% from FY2020 to FY2025. Annual revenue decreased from $1.9M in FY2021 to $785,151 in FY2022, rebounded to $1.0M in FY2023, and contracted to $12,000 in FY2024 before reaching $86,000 in FY2025. Net losses were -$8.2M in FY2021, -$14.9M in FY2022, -$73.5M in FY2023, -$18.5M in FY2024, and -$46.9M in FY2025, when diluted EPS was -$29.99. R&D expense stood at $10.7M in FY2025 after peaking at $19.3M in FY2024. For the latest quarter ended June 30, 2026, revenue was $0, representing a quarterly revenue decline of 100.0% year-over-year, while trailing twelve-month EPS was -$1.66.
Balance sheet and cash flow
As of June 30, 2026, the company held $67.7M in cash and short-term investments, with total debt of $96,000, producing net cash of $67.6M. Liquidity is supported by a current ratio of 48.81 and a debt-to-equity ratio of 0.00 against shareholders' equity of $67.4M. Operating cash flow in FY2025 was -$12.5M, yielding free cash flow of -$12.5M. In FY2026, capital expenditures were $10,000, while the 5-year share count change was 28.8%.
Valuation and performance
Incannex Healthcare trades at a market capitalization of $35.4M and an enterprise value of -$33.1M. The stock trades at a price-to-book multiple of 0.5x and a forward price-to-earnings ratio of 3.8x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio of 84.2x is elevated relative to the US-listed Healthcare peer median of 4.1x. Over the past year, the stock declined 73.1%, underperforming the S&P 500 return of 16.8%.
What analysts expect
Wall Street coverage consists of 1 Strong Buy rating, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $18.64, representing a potential upside of 561.0% from the last close of $2.82. Analysts forecast an EPS of -$2.23 and revenue of $0 for the fiscal year ending June 30, 2027, followed by an EPS of -$2.44 on $0 revenue for the next fiscal year. Incannex beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 13, 2026.
Key risks and what to watch
- High operational cash burn, reflected in free cash flow of -$12.5M in FY2025, could deplete the current cash balance of $67.7M without commercial revenue.
- Substantial dilution risk remains visible after the share count increased 28.8% over the past 5 years to support clinical programs.
- Extreme price volatility is indicated by a beta of 2.82 alongside a 73.7% year-to-date decline.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IXHL AI stock analysis
This page is an AI-written research summary of Incannex Healthcare Limited (IXHL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IXHL income statement, IXHL balance sheet, IXHL key metrics, IXHL analyst forecast, IXHL chart. See the IXHL stock overview for the latest quote and news.
IXHL AI stock analysis FAQ
Does Incannex Healthcare pay a dividend?
No, Incannex Healthcare does not pay a dividend, as its trailing twelve-month revenue is $0 and capital is allocated to clinical development.
What is Incannex Healthcare's net cash position?
As of June 30, 2026, Incannex held $67.7M in cash and short-term investments and $96,000 in total debt, resulting in net cash of $67.6M.
What are analysts forecasting for IXHL's financial performance?
For the fiscal year ending June 30, 2027, analysts estimate revenue of $0 and an EPS of -$2.23, followed by an EPS estimate of -$2.44 for the next fiscal year.
When is the next earnings announcement for IXHL?
The company's next earnings date is scheduled for November 13, 2026.